Premium
Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co‐administration
Author(s) -
LorenzoPinto A.,
GiménezManzorro Á.,
RodríguezGonzález C. G.,
AhumadaJiménez A.,
HerranzAlonso A.,
MarzalAlfaro M. B.,
SanjurjoSáez M.
Publication year - 2016
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12403
Subject(s) - ombitasvir , dasabuvir , ritonavir , paritaprevir , medicine , acenocoumarol , pharmacy , pharmacology , virology , ribavirin , warfarin , human immunodeficiency virus (hiv) , hepatitis c virus , viral load , virus , antiretroviral therapy , atrial fibrillation , family medicine
Summary What is known and objective Limited data are available on co‐administration of acenocoumarol with direct‐acting antiviral agents for chronic hepatitis C virus infection. Case summary We report a case of a patient who required a significant increase in acenocoumarol weekly dose probably due to an interaction with ombitasvir/paritaprevir/ritonavir and/or dasabuvir. A causality assessment of the drug–drug interaction leading to a reduced INR was conducted according to the Naranjo algorithm. A score of 6 suggested that the adverse drug reaction was probable. What is new and conclusion Because of possible INR abnormalities during the concomitant use of acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir, clinicians should closely monitor INR values.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom